Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 233 clinical trials
Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) (GENSA)

The natural history of non-muscle-invasive bladder cancer is characterised by recurrence and progression. We compare the effectiveness of gemcitabine hydrochloride and epirubicin hydrochloride, in combination with continuous saline irrigation, as an immediate single intravesical instillation in the potential reduction of the disease recurrence as well as progression.

bladder tumor
transurethral resection
invasive bladder cancer
gemcitabine
  • 0 views
  • 22 Mar, 2022
  • 1 location
A Phase Ib/II Study to Assess the Safety and Activity of DURvalumab (MEDI4736) in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE)

DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).

gilbert's syndrome
durvalumab
radical cystectomy
invasive bladder cancer
bladder tumor
  • 0 views
  • 12 Oct, 2022
  • 3 locations
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

invasive bladder cancer
pembrolizumab
bladder tumor
carcinoma
measurable disease
  • 0 views
  • 22 Mar, 2022
  • 1 location
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PF-07225570 alone or in combination with an anti-PD-1 antibody in participants with recurrent non-muscle invasive bladder cancer. This study consists of 2 parts, single agent dose escalation (Part 1A), dose finding of …

bladder tumor
radical cystectomy
carcinoma
invasive bladder cancer
  • 0 views
  • 04 Oct, 2022
  • 2 locations
Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors (URODX-FGFR3)

This study is a case-control, propsective and muticentric clinical trial, which aim to compare the specificity and sensibility of VisioCyt urinary cytological test combined with FGFR3 mutation detection test to VisioCyt urinary cyological test on its own to detect bladder cancer. The case are patient in whom newly diagnosed, or …

bladder tumor
FGFR3
  • 0 views
  • 26 Apr, 2022
  • 1 location
Checkpoint Inhibitor and Radiation Therapy in Bulky Node-Positive Bladder Cancer

Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy. Immune checkpoint inhibitor (ICI) therapy is FDA-approved in advanced bladder cancer for patients unable to receive or failing to respond to platinum-based chemotherapy. The present …

nivolumab
advanced urothelial carcinoma
carcinoma
transurethral resection
pembrolizumab
  • 0 views
  • 07 Oct, 2021
  • 1 location
Care Planning Framework in Advanced Bladder Cancer (ABC123)

Pilot study assessing the feasibility and acceptability of the ABC123 framework, as well as goal concordance between patient and clinician stated goals. Patients >60 years old with recently diagnosed advanced, incurable bladder cancer making an initial treatment decision will be enrolled. The team will pilot test the ABC123 framework delivery …

bladder tumor
carcinoma
  • 0 views
  • 14 Jun, 2022
  • 1 location
Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer (BCG+MM)

Open label, randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer. The study aim is to compare disease-free survival between treatment arms: BCG alone versus Mitomycin in addition to BCG.

invasive bladder cancer
cystoscopy
carcinoma in situ
cancer
carcinoma
  • 16 views
  • 07 Oct, 2022
  • 14 locations
Relationship Between Lymph Node Dissection and Prognosis in High-risk NMIBC

There is no consensus on the need for lymph node dissection in radical cystectomy (RC) for high-risk non-muscular invasive bladder cancer (NMIBC). Investigators divided participants at high risk of NMIBC without enlarged lymph nodes as indicated by pelvic MRI into two groups 1:1. One group of participants underwent RC combined …

radical cystectomy
invasive bladder cancer
bladder tumor
neutrophil count
transurethral bladder excision
  • 0 views
  • 24 Nov, 2021
  • 1 location
Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery (MACS)

The current usage of antibiotic prophylaxis (AP) in radical cystectomy (RC) is aimed to reducing the incidence of surgical site infections and incidence of unnecessary prescribing of antibiotics. There are a huge number of different AP protocols according to Urological Associations. However, there is no convincing evidence to support variations …

urinary diversion
radical cystectomy
bladder carcinoma
carcinoma
  • 0 views
  • 16 Jun, 2022
  • 1 location